Overall, these results demonstrate that beta-Pompilidotoxin SP600125 reduces the growth of DOX-resistant cancer cells. In addition, inhibition of the Jnk pathway is an effective treatment for DOX-resistance cancer cells. This study may contribute to improving various combination-chemotherapeutic treatments of cancer patients who develop resistance to DOX.
Acknowledgments
This work was supported by the Korea Research Foundation Grant funded by the Korean Government (KRF-2008-313-E00431).
Appendix A. Supplementary data
Supplementary Fig. 1.
DOX-resistant breast cancer cells show reduced viability after increasing the amount and exposure-time of DOX. (A and B) The MCF71, Hs578T, MDA-MB2311, MCF72, MCF7-R, and MDA-MB2312 cells were plated on 96-well plates and grown to 50% confluence. The cells were then stimulated for 24 or 48 h with 3, 5, or 9 μM DOX (white bars), or not treated (0 μM; gray bar). The MTS assay was performed as described in Materials and methods.
Figure optionsDownload full-size imageDownload as PowerPoint slide
View User's Journal
Fluoxetine is primarily excreted as a parental
 |
